Literature DB >> 19151110

The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine.

M R Namazi1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19151110     DOI: 10.1177/0961203308097574

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


× No keyword cloud information.
  6 in total

Review 1.  The Diagnosis and Treatment of Systemic Lupus Erythematosus.

Authors:  Annegret Kuhn; Gisela Bonsmann; Hans-Joachim Anders; Peter Herzer; Klaus Tenbrock; Matthias Schneider
Journal:  Dtsch Arztebl Int       Date:  2015-06-19       Impact factor: 5.594

Review 2.  Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis.

Authors:  Stephan Pflugbeil; Karin Böckl; Reinhold Pongratz; Marianne Leitner; Winfried Graninger; Astrid Ortner
Journal:  Rheumatol Int       Date:  2020-02-12       Impact factor: 2.631

3.  Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?

Authors:  Şeyma Taştemur; Hilmi Ataseven
Journal:  Med Hypotheses       Date:  2020-06-20       Impact factor: 1.538

Review 4.  Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.

Authors:  Guillaume Hache; Jean Marc Rolain; Philippe Gautret; Jean-Claude Deharo; Philippe Brouqui; Didier Raoult; Stéphane Honoré
Journal:  Microb Drug Resist       Date:  2021-03       Impact factor: 3.431

Review 5.  The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review.

Authors:  Subham Das; Anu Kunnath Ramachandran; Sumit Raosaheb Birangal; Saleem Akbar; Bahar Ahmed; Alex Joseph
Journal:  Med Drug Discov       Date:  2021-03-10

Review 6.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.